Literature DB >> 12447933

Changes of sodium channel expression in experimental painful diabetic neuropathy.

Matthew J Craner1, Joshua P Klein, Muthukrishnan Renganathan, Joel A Black, Stephen G Waxman.   

Abstract

Although pain is experienced by many patients with diabetic neuropathy, the pathophysiology of painful diabetic neuropathy is not understood. Substantial evidence indicates that dysregulated sodium channel gene transcription contributes to hyperexcitability of dorsal root ganglion neurons, which may produce neuropathic pain after axonal transection. In this study, we examined sodium channel mRNA and protein expression in dorsal root ganglion neurons in rats with streptozotocin-induced diabetes and tactile allodynia, using in situ hybridization and immunocytochemistry for sodium channels Na(v)1.1, Na(v)1.3, Na(v)1.6, Na(v)1.7, Na(v)1.8, and Na(v)1.9. Our results show that, in rats with experimental diabetes, there is a significant upregulation of mRNA for the Na(v)1.3, Na(v)1.6, and Na(v)1.9 sodium channels and a downregulation of Na(v)1.8 mRNA 1 and 8 weeks after onset of allodynia. Channel protein levels display parallel changes. Our results demonstrate dysregulated expression of the genes for sodium channels Na(v)1.3, Na(v)1.6, Na(v)1.8, and Na(v)1.9 in dorsal root ganglion neurons in experimental diabetes and suggest that misexpression of sodium channels contributes to neuropathic pain associated with diabetic neuropathy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12447933     DOI: 10.1002/ana.10364

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  45 in total

1.  The sodium channel {beta}3-subunit induces multiphasic gating in NaV1.3 and affects fast inactivation via distinct intracellular regions.

Authors:  Fiona S Cusdin; Daniel Nietlispach; Joseph Maman; Timothy J Dale; Andrew J Powell; Jeffrey J Clare; Antony P Jackson
Journal:  J Biol Chem       Date:  2010-07-30       Impact factor: 5.157

2.  Maladaptive dendritic spine remodeling contributes to diabetic neuropathic pain.

Authors:  Andrew M Tan; Omar A Samad; Tanya Z Fischer; Peng Zhao; Anna-Karin Persson; Stephen G Waxman
Journal:  J Neurosci       Date:  2012-05-16       Impact factor: 6.167

Review 3.  Sodium channels and pain: from toxins to therapies.

Authors:  Fernanda C Cardoso; Richard J Lewis
Journal:  Br J Pharmacol       Date:  2017-09-02       Impact factor: 8.739

Review 4.  Neuropathic pain in diabetes--evidence for a central mechanism.

Authors:  Tanya Z Fischer; Stephen G Waxman
Journal:  Nat Rev Neurol       Date:  2010-07-13       Impact factor: 42.937

Review 5.  Reappraising neuropathic pain in humans--how symptoms help disclose mechanisms.

Authors:  Andrea Truini; Luis Garcia-Larrea; Giorgio Cruccu
Journal:  Nat Rev Neurol       Date:  2013-09-10       Impact factor: 42.937

Review 6.  Regulating excitability of peripheral afferents: emerging ion channel targets.

Authors:  Stephen G Waxman; Gerald W Zamponi
Journal:  Nat Neurosci       Date:  2014-01-28       Impact factor: 24.884

Review 7.  The role of sodium channels in painful diabetic and idiopathic neuropathy.

Authors:  Giuseppe Lauria; Dan Ziegler; Rayaz Malik; Ingemar S J Merkies; Stephen G Waxman; Catharina G Faber
Journal:  Curr Diab Rep       Date:  2014-10       Impact factor: 4.810

Review 8.  Pharmacological treatment of diabetic neuropathic pain.

Authors:  Howard S Smith; Charles E Argoff
Journal:  Drugs       Date:  2011-03-26       Impact factor: 9.546

Review 9.  Uses of skin biopsy for sensory and autonomic nerve assessment.

Authors:  M Iliza Myers; Amanda C Peltier
Journal:  Curr Neurol Neurosci Rep       Date:  2013-01       Impact factor: 5.081

10.  Global transcriptional programs in peripheral nerve endoneurium and DRG are resistant to the onset of type 1 diabetic neuropathy in Ins2 mice.

Authors:  Anne-Sophie de Preux Charles; Valérie Verdier; Jennifer Zenker; Bastian Peter; Jean-Jacques Médard; Thierry Kuntzer; Jacques S Beckmann; Sven Bergmann; Roman Chrast
Journal:  PLoS One       Date:  2010-05-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.